ViewRay, Inc. designs, manufactures, and markets radiation therapy systems. The company offers MRIdian, a magnetic resonance image guided radiation therapy system to image and treat cancer patients. Its MRIdian integrates MRI technology, radiation delivery, and proprietary software to see the soft tissues, shape the dose to accommodate for changes in anatomy, and strike the target using real-time targeting throughout the treatment. The company serves university research and teaching hospitals, community hospitals, private practices, government institutions, and freestanding cancer centers. ViewRay, Inc. markets its MRIdian through a direct sales force and distribution network. It has operations in the United States, France, Germany, Taiwan, the United Kingdom, and internationally. The company was founded in 2004 and is headquartered in Oakwood, Ohio.
IPO Year:
Exchange: NASDAQ
Website: viewray.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/11/2023 | $4.00 → $1.00 | Buy → Neutral | B. Riley Securities |
| 4/17/2023 | $7.00 → $1.25 | Buy → Hold | Jefferies |
| 4/14/2023 | Outperform → Perform | Oppenheimer | |
| 4/14/2023 | Buy → Neutral | BTIG Research | |
| 4/14/2023 | $7.00 → $1.75 | Buy → Hold | Stifel |
| 1/25/2022 | $7.00 | Buy | Stifel |
| 1/11/2022 | $7.00 | Neutral → Buy | B. Riley Securities |
| 10/14/2021 | $7.00 | Neutral | B. Riley Securities |
| 6/25/2021 | Underweight → Equal-Weight | Morgan Stanley |
25-NSE - ViewRay, Inc. (0001597313) (Subject)
8-K - ViewRay, Inc. (0001597313) (Filer)
NT 10-Q - ViewRay, Inc. (0001597313) (Filer)
144 - ViewRay, Inc. (0001597313) (Subject)
144 - ViewRay, Inc. (0001597313) (Subject)
8-K - ViewRay, Inc. (0001597313) (Filer)
144 - ViewRay, Inc. (0001597313) (Subject)
144 - ViewRay, Inc. (0001597313) (Subject)
144 - ViewRay, Inc. (0001597313) (Subject)
144 - ViewRay, Inc. (0001597313) (Subject)
4 - ViewRay, Inc. (0001597313) (Issuer)
4 - ViewRay, Inc. (0001597313) (Issuer)
3 - ViewRay, Inc. (0001597313) (Issuer)
3 - ViewRay, Inc. (0001597313) (Issuer)
4 - ViewRay, Inc. (0001597313) (Issuer)
4 - ViewRay, Inc. (0001597313) (Issuer)
4 - ViewRay, Inc. (0001597313) (Issuer)
4 - ViewRay, Inc. (0001597313) (Issuer)
4 - ViewRay, Inc. (0001597313) (Issuer)
4 - ViewRay, Inc. (0001597313) (Issuer)
B. Riley Securities downgraded ViewRay from Buy to Neutral and set a new price target of $1.00 from $4.00 previously
Jefferies downgraded ViewRay from Buy to Hold and set a new price target of $1.25 from $7.00 previously
Oppenheimer downgraded ViewRay from Outperform to Perform
BTIG Research downgraded ViewRay from Buy to Neutral
Stifel downgraded ViewRay from Buy to Hold and set a new price target of $1.75 from $7.00 previously
Stifel initiated coverage of ViewRay with a rating of Buy and set a new price target of $7.00
B. Riley Securities upgraded ViewRay from Neutral to Buy and set a new price target of $7.00
B. Riley Securities resumed coverage of ViewRay with a rating of Neutral and set a new price target of $7.00
Morgan Stanley upgraded ViewRay from Underweight to Equal-Weight
Guggenheim upgraded ViewRay from Neutral to Buy and set a new price target of $7.00
NUBURU, Inc. ("NUBURU" or the "Company") (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced the appointment of Brian Knaley as the Company's new Chief Executive Officer, replacing Dr. Mark Zediker, who has left the Company to pursue other opportunities. Mr. Knaley has also joined NUBURU's Board of Directors upon assuming the role. Mr. Knaley, who had served as the Company's Chief Financial Officer since February 2022, has over 25 years of experience in finance and operations. Prior to joining NUBURU, Mr. Knaley served as the chief financial officer of CEA Industries Inc. (NASDAQ:CEAD), a provider of controlled environmental
DENVER, Jan. 9, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2022. The preliminary results have not been audited and are subject to change. Selected Fourth Quarter and Full Year 2022 Preliminary Results and Other Data (Unaudited)Received nine new orders for MRIdian systems totaling approximately $56 million, compared to seven new orders totaling approximately $41 million in the fourth quarter of 2021. A total of 32 orders were received for the twelve months ended December 31, 2022, compared to 28 orders for the twelve months ended December 31, 2021. Total backlog i
Three-time public company CFO joins NUBURU with deep experience in leading business transformation and optimization of financial processes on a global scale NUBURU®, the industry leader in high power and high brightness industrial blue lasers, today announced that it has appointed Brian Knaley as Chief Financial Officer. In this strategic role, Mr. Knaley will oversee all aspects of finance and investor relations as NUBURU accelerates and implements its growth strategy to expand the presence of its blue laser technology across target markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322005131/en/Three-time public compan
CLEVELAND, Feb. 11, 2021 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY) announced the appointment of Phil Spencer to its Board of Directors, effective February 9, 2021. Mr. Spencer has a long track record of delivering substantial financial value as a CEO and board member over the last 20 years. He is currently the President and CEO of Mega-Broadband Investments (MBI), a private-equity backed top-10 US cable operator that acquires and invests in rural-focused cable systems. MBI recently acquired Northland Communications, Eagle Communications, Vyve Broadband, and FamilyView Cable, and currently passes 650,000 homes & businesses in fifteen states. Prior to MBI, Phil was Chief Executive Office
NUBURU, Inc. ("NUBURU" or the "Company") (NYSE:BURU), a leading innovator in high-power and high-brightness industrial blue laser technology, today announced the appointment of Brian Knaley as the Company's new Chief Executive Officer, replacing Dr. Mark Zediker, who has left the Company to pursue other opportunities. Mr. Knaley has also joined NUBURU's Board of Directors upon assuming the role. Mr. Knaley, who had served as the Company's Chief Financial Officer since February 2022, has over 25 years of experience in finance and operations. Prior to joining NUBURU, Mr. Knaley served as the chief financial officer of CEA Industries Inc. (NASDAQ:CEAD), a provider of controlled environmental
DENVER, July 21, 2023 /PRNewswire/ -- ViewRay, Inc. (the "Company") (NASDAQ:VRAY) announced today that on July 17, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"). Nasdaq has determined that due to the Company's voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code, and concerns about the Company's ability to sustain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on Nasdaq based on Listing Rule 5450(a)(1), the Company's securities will be delisted from the Nasdaq Stock Market. The Company does not intend to appeal Nasdaq's determination. Trading of the Company's common st
Debtor-in-Possession Financing Secured to Support Ongoing Operations and Chapter 11 Process DENVER, July 17, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that it and certain of its subsidiaries (collectively, "the Company") filed voluntary petitions for relief (the "Petitions") under Chapter 11 of Title 11 the U.S. Bankruptcy Code ("Chapter 11") in the United States Bankruptcy Court for the District of Delaware (the "Court"). The Company further disclosed that it intends to pursue a sale of its business under Section 363 of the Bankruptcy Code, including a sale of all or a portion of the Company's assets, while continuing to support its customers during the Chapter 11 pro
First cancer center in Oklahoma and fourth VA medical center to offer advanced MRI-guided radiation therapy to treat cancer. DENVER, June 13, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that the VA Oklahoma City Healthcare System has selected MRIdian MRI-guided radiation therapy system to expand radiation therapy services at the Oklahoma City VA Medical Center. This will be the first cancer center in Oklahoma and the fourth VA medical center offering Veterans access to MRIdian's advanced MRI-guided radiation therapy to treat cancer. The MRIdian system will enable the Oklahoma City VA Medical Center to provide precision MRI-guided radiation therapy technology to Veterans
50 clinical presentations and posters highlight benefits of MRI-guided radiation adaptive therapy DENVER, May 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that the company's MRIdian MRI-guided radiation therapy system will be featured at the Annual Meeting of the European Society for Radiotherapy and Oncology (ESTRO) with over 50 presentations and posters highlighting MRIdian clinical and research experience. This year's ESTRO meeting will be held May 12-16, 2023, in Vienna, Austria. MRIdian-focused presentations and posters, submitted by MRIdian clinical teams from across the globe and accepted as part of ESTRO's Scientific Sessions, highlight MRIdian's clinical valu
DENVER, May 10, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Total revenue for the first quarter 2023 was approximately $22.5 million, primarily from three revenue units, compared to approximately $18.9 million, primarily from three revenue units, in the first quarter of 2022.Received 13 new orders for MRIdian systems, totaling $68.3 million.Total backlog increased to $411.0 million as of March 31, 2023, compared to approximately $331.0 million as of March 31, 2022.Cash and cash equivalents, inclusive of restricted cash, was $85.5 million as of March 31, 2023.Net l
DENVER, May 9, 2023 /PRNewswire/ --ViewRay, Inc. (NASDAQ:VRAY) announced today details relating to the release of first quarter 2023 financial results. ViewRay will hold a conference call to discuss results on Wednesday, May 10, 2023 at 4:30 p.m. ET. The dial-in number is (833) 470-1428 for domestic callers. The confirmation number is 133683. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars." About ViewRay® ViewRay, Inc. (NASDAQ:VRA
DENVER, April 13, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today provided a business update and announced preliminary financial results for the quarter ended March 31, 2023. The preliminary results have not been audited and are subject to change. First Quarter 2023 Preliminary Results and Key Points (Unaudited) Received 13 new orders for MRIdian systems totaling approximately $68 million, compared to seven new orders totaling approximately $41 million in the first quarter of 2022.Total backlog increased to approximately $411 million as of March 31, 2023, compared to approximately $331 million as of March 31, 2022.Total revenue for the first quarter 2023 was approximat
DENVER, April 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET. The dial-in number for domestic callers is (888) 886-7786. The confirmation number is 56031524. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars". About ViewRay® ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MR
First and only MRIdian in the Czech Republic to bring advanced MRI-guided radiation therapy to the region DENVER, March 7, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) today announced the Czech Ministry of Health has approved the purchase of ViewRay's MRIdian system to bring advanced MRI-guided radiation therapy to treat its cancer patients at the Military University Hospital Prague in the Czech Republic. This is the first and only hospital to offer the precision of MRIdian Stereotactic MRI-guided Adaptive Radiotherapy (SMART) in the Czech Republic. The purchase was co-financed by the REACT-EU financial instrument and the founder's contribution, the Ministry of Defense of the Czech Repub
DENVER, May 10, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced financial results for the first quarter ended March 31, 2023. First Quarter 2023 Highlights Total revenue for the first quarter 2023 was approximately $22.5 million, primarily from three revenue units, compared to approximately $18.9 million, primarily from three revenue units, in the first quarter of 2022.Received 13 new orders for MRIdian systems, totaling $68.3 million.Total backlog increased to $411.0 million as of March 31, 2023, compared to approximately $331.0 million as of March 31, 2022.Cash and cash equivalents, inclusive of restricted cash, was $85.5 million as of March 31, 2023.Net l
DENVER, May 9, 2023 /PRNewswire/ --ViewRay, Inc. (NASDAQ:VRAY) announced today details relating to the release of first quarter 2023 financial results. ViewRay will hold a conference call to discuss results on Wednesday, May 10, 2023 at 4:30 p.m. ET. The dial-in number is (833) 470-1428 for domestic callers. The confirmation number is 133683. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars." About ViewRay® ViewRay, Inc. (NASDAQ:VRA
DENVER, April 12, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) will hold a conference call to discuss results on Thursday, April 13, 2023, at 8:00 AM ET. The dial-in number for domestic callers is (888) 886-7786. The confirmation number is 56031524. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website under "Events and Webinars". About ViewRay® ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian® MR-Guided Radiation Therapy System. MR
DENVER, Feb. 27, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced financial results for the fourth quarter and full fiscal year ended December 31, 2022. Full Year 2022 Highlights Total revenue of $102.2 million primarily from 16 revenue units including one upgrade, compared to 2021 revenue of approximately $70.1 million, primarily from ten revenue units.Received a total of 32 orders for the twelve months ended December 31, 2022, totaling $191.0 million, compared to 28 total orders totaling $158.9 million in 2021.Total backlog increased to approximately $380.2 million as of December 31, 2022, compared to approximately $313.4 million as of December 31, 2021.Cas
DENVER, Jan. 31, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today details relating to the release of fourth quarter 2022 financial results. ViewRay will hold a conference call to discuss results on Monday, February 27, 2023 at 4:30 p.m. ET. The dial-in numbers are (888) 396-8049 for domestic callers. The confirmation number is 47314692. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available o
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China DENVER, Jan. 5, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today that Chindex Medical Limited (Chindex), through its subsidiary, has ordered 10 MRIdian® MR-Guided Therapy Systems. Chindex, a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma), has been ViewRay's distribution partner since 2019. MRIdian received regulatory approval in September 2022 from the National Medical Products Administration (NMPA), allowing for its sale and utilization throughout China. This approval expands MRIdian's global reach and offers cancer patients a new radiation
DENVER, Nov. 1, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced financial results for the third quarter ended September 30, 2022. Third Quarter 2022 Highlights Total revenue for the third quarter 2022 was approximately $26.5 million, primarily from four revenue units, compared to approximately $19.2 million, primarily from three revenue units, in the third quarter of 2021.Received eight new orders for MRIdian systems totaling $47.5 million, compared to seven new orders totaling $39.4 million in the third quarter 2021.Total backlog increased to $370.5 million as of September 30, 2022, compared to approximately $295.1 million as of September 30, 2021.Cash and c
DENVER, Oct. 14, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today details relating to the release of third quarter 2022 financial results. ViewRay will hold a conference call to discuss results on Tuesday, November 1, 2022, at 5:00 p.m. ET. If you wish to participate live via teleconference please click here to obtain your dial-in and individual passcode. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at https://investors.viewray.com/events-and-webinars. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's website, under "Events and Webinars". About Vie
CLEVELAND, Aug. 2, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) (the "Company") today announced financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Highlights Total revenue for the second quarter 2022 was approximately $22.1 million, primarily from three revenue units and one upgrade, compared to approximately $15.0 million, primarily from two revenue units, in the second quarter of 2021.Received eight new orders for MRIdian systems totaling $46.3 million, compared to seven new orders totaling $37.9 million in the second quarter 2021.Total backlog increased to $352.8 million as of June 30, 2022, compared to approximately $278.4 million as of June 30, 2021.Ca
CLEVELAND, July 19, 2022 /PRNewswire/ -- ViewRay, Inc. (NASDAQ:VRAY) announced today details relating to the release of its first quarter 2022 financial results. ViewRay will hold a conference call to discuss results on Tuesday, August 2, 2022 at 4:30 p.m. ET. The dial-in numbers are (646) 307-1952 for domestic callers and (888) 672-2415 for international callers. The confirmation number is 7750966. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at http://investors.viewray.com/events-and-presentations/upcoming-events. After the live webcast, a replay will remain available online on the investor relations page of ViewRay's
SC 13G/A - ViewRay, Inc. (0001597313) (Subject)
SC 13G/A - ViewRay, Inc. (0001597313) (Subject)
SC 13G/A - ViewRay, Inc. (0001597313) (Subject)
SC 13G/A - ViewRay, Inc. (0001597313) (Subject)
SC 13D/A - ViewRay, Inc. (0001597313) (Subject)
SC 13D/A - ViewRay, Inc. (0001597313) (Subject)
SC 13G/A - ViewRay, Inc. (0001597313) (Subject)
SC 13D/A - ViewRay, Inc. (0001597313) (Subject)
SC 13D - ViewRay, Inc. (0001597313) (Subject)
SC 13G/A - ViewRay, Inc. (0001597313) (Subject)